iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody

By Ray Dogum, Chief Editor, Drug Discovery Online

As GLP-1 receptor agonists reshape obesity care, a new question is moving to the center of drug development: how can patients lose fat without sacrificing muscle and long-term metabolic health?

iBio, Inc. is positioning its lead clinical candidate, iBio600, around that gap. The company is not trying to outcompete GLP-1s on appetite suppression. Instead, it is developing a long-acting antibody intended to complement them by preserving lean muscle during weight loss.

In a recent Drug Discovery Online interview, iBio CEO and chief scientific officer Martin Brenner described the strategy as part of a broader shift from weight loss alone to “quality weight loss”—reducing metabolically harmful fat while maintaining the tissue patients need for strength, function, and durability.

The GLP-1 Gap: Body Composition

GLP-1 therapies from Novo Nordisk, Lilly, and others have demonstrated unprecedented weight-loss efficacy, but Brenner emphasized that weight reduction can come with a meaningful trade-off.

“When patients lose weight—whether through diet or GLP‑1s—they’re also losing muscle,” he explained.

Brenner estimated that “for every kilogram of weight lost, patients may lose roughly 300 grams of muscle. When weight is regained, only 80 grams of that muscle returns. Over repeated cycles, that imbalance can contribute to progressive muscle depletion, frailty risk, and poorer long-term outcomes.”

He added, “Frail people don't have the stability, they fall, and their bones break easier. Muscle pulls really hard on bones, and that keeps the bone density high and keeps the bone healthy.”

A Muscle-Preservation Add-On

iBio600 is designed to inhibit myostatin and GDF11, two TGF-beta family ligands involved in suppressing muscle growth.

Preclinical data in non-human primates suggest the antibody may help retain muscle while reducing fat mass, with the GDF11 component potentially contributing metabolic effects beyond muscle biology. Those findings are central to iBio’s case because they provide translational evidence in a model closer to human physiology than rodents.

“We don’t think of this as another way to make people eat less,” Brenner said. “The goal is to change what happens to the body during weight loss.”

Epitope Design Meets Wet-Lab Validation

A key part of iBio600’s differentiation is where it binds. Because myostatin and GDF11 are structurally related but not biologically interchangeable, iBio’s dual-target profile depends on identifying an epitope that is functionally relevant across both ligands without creating an unwanted binding profile.

According to the company, its platform uses epitope steering and computational antigen design to present defined target regions in formats that favor antibodies with the desired specificity and mechanism. Brenner framed the company’s use of AI less as a model-building competition and more as an effort to connect in silico design with biological execution.

“We’re trying to stay out of the race to the bottom for new models to predict things,” Brenner said. “What we are really focusing on is how do we integrate these tools into our wet lab workflow. In the end, the most important piece for us is what comes out at the end. And this is a molecule that can actually be developed into a drug.”

“The target biology matters, but the epitope matters just as much,” Brenner said. “If you bind the wrong surface, you may have a beautiful antibody that doesn’t deliver the biology you need.”

That hybrid approach—computational design, mammalian display, high-dimensional selection, and experimental validation—is meant to bias discovery toward antibodies that are not only novel, but developable and manufacturable.

The same design logic extends to half-life. iBio has reported Fc engineering that improved FcRn binding relative to a standard IgG4 backbone, supporting extended exposure in non-human primates and a projected human half-life of roughly 100 to 150 days.

Long-Acting Design for a Chronic Disease

That durability matters because obesity is chronic. A long-acting antibody could reduce troughs in target coverage and better support sustained muscle preservation during prolonged treatment.

“With shorter-acting antibodies, you have troughs where the drug isn’t working as effectively,” Brenner explained. “A long-acting molecule can eliminate many of those gaps.”

“And having a long-acting antibody, you cut multiple of these troughs out. And it's complex, because myostatin acts on muscle. Antibodies float around in blood, so for antibodies to reach muscle, they had to get out of the blood vessels, into the muscle. It’s been shown that only 4% of the antibodies in blood will actually make it to muscle,” Brenner said.

Combination Strategy

Commercially, iBio’s strategy reflects the likelihood that obesity treatment will move toward combination regimens. Rather than competing directly with established GLP-1 leaders, the company is pursuing a complementary role for developers looking to differentiate beyond weight-loss percentage alone.

“Our view was always that GLP‑1s were going to be very successful,” Brenner said. “So the question became: what can we add that makes that success healthier and more durable?”

“There are many GLP‑1s in development,” he said. “Not all of them are going to win on weight-loss percentage alone.”

“We’re not interested in cosmetic changes,” he said. “We want to reduce the tissue that makes patients sick while retaining the tissues that keep them healthy.”

Platform Implications

Their next lead candidate, iBio610, shows how the same platform logic could extend to other difficult targets. The program targets Activin E, another TGF-beta family member, and reflects iBio’s thesis that AI is most useful when embedded in biological workflows rather than used in isolation.

Brenner said that approach may not replicate natural antibody diversity exactly, but it can generate unusually high hit rates when paired with the right biological models. “That allowed us to go from a paper exercise, where we literally just sketched out what characteristics this molecule should have, to a development candidate in 7 months,” he said. “That can take up to 2 years, usually. So that was a significant acceleration of time.”

Just as important, Brenner framed that acceleration as a benefit with clear limits. “From that point on, AI doesn’t play a role anymore,” he said. “It’s cell line development, it’s manufacturing. We always joke about people who claim to make AI drugs. In our hands, AI enables 3 or 4 steps in drug discovery. It takes more than 10,000 steps to make a medicine.”

The Next Obesity Question

GLP-1s have changed what is possible in obesity care. iBio’s wager is that the next competitive frontier will be less about inducing weight loss and more about improving what that weight loss is made of.

With iBio600 now in phase 1 safety trials, the company is testing whether muscle preservation can become a central pillar of next-generation obesity treatment and whether a computationally guided biologics platform can produce real medicines.